Rank #1879CRNX

Crinetics Pharmaceuticals, Inc.

$44.00

1.27% (Daily)

Market Cap

$4.51B

Revenue

$1.53M

Rank by MCap

#1879

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. R. Scott Struthers Ph.D.

Headquarters

San Diego, CA

Employees

437

About Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in a Phase 3 clinical trial for the treatment of acromegaly and carcinoid syndrome associated with neuroendocrine tumors. It is also developing Atumelnan...